Who is sponsoring NCT01340768?

NCT01340768 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT01340768 study?

NCT01340768 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT01340768?

Interventions: Sitagliptin, Sulfonylurea, Metformin.

What is the status of NCT01340768?

NCT01340768 is currently COMPLETED.

Last reviewed 2017-06-05 · How we verify

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

NCT01340768 PHASE3 COMPLETED Results posted

This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast during the month of Ramadan. The primary hypothesis is that during the 30 days of Ramadan fasting, treatment with sitagliptin (with or without metformin) compared to SU treatment (with or without metformin) results in a lower incidence of hypoglycemia in participants with T2DM.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE3
Status	COMPLETED
Enrolment	870
Start date	Tue Jun 22 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 21 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Type 2 Diabetes Mellitus

Interventions

Sitagliptin
Sulfonylurea
Metformin